New Chairman at OCC

Øyvind Kongstun Arnesen is appointed new chairman at Oslo Cancer Cluster (OCC).

35 years since the start of Sweden’s first science park

On June 9th, 1983, the groundbreaking for Sweden’s first Science Park – Ideon – took place! The area, Pålsjö meadows, looked very different then, as the name hints, it was mostly meadows and farmland.

AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

You can not survive tomorrow if you don’t have partnerships – Visioning the future

During Skåne Innovation Week, we gathered some sharp minds to envision the future with us. Together with Andreas Bergh, Lund University, Olof Dellien, Arm, Martin Gren, Axis Communications, P-A Hedin, Sigma Connectivity, Jeanna Kimbré and Johan Svenér, Sony and Henrik Wiberg, Volvo Car Sverige we talked about future trends, challenges and opportunities. We were guided through the day by the amazing Trine Grönlund.

AI Speeds Up Pharmaceutical Testing

Oslo Cancer Cluster member Immunitrack has landed investments worth millions. The money will be used to develop a computer program that can predict how the immune system will react to different substances.

AbbVie Teams Up with Hidradenitis Suppurativa Patients Around the World to Raise Awareness About the Disease

Hidradenitis suppurativa (HS) is a painful, debilitating, chronic inflammatory skin disease estimated to affect 1 - 4 percent of the world's population(1),(2). Voices of HS Unite encourages people affected by HS to share their stories online, to raise awareness, reduce stigma and to have a conversation with their dermatologist